Detalles de la búsqueda
1.
Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients' preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer.
BMC Cancer
; 20(1): 286, 2020 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32252684
2.
Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting.
Breast Care (Basel)
; 19(1): 49-61, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38384487
3.
Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Horm Mol Biol Clin Investig
; 32(2)2017 Sep 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-28937963
4.
Neoadjuvant chemotherapy for breast cancer with weekly nab-paclitaxel followed by epirubicin and cyclophosphamide--results of a case series.
In Vivo
; 28(2): 235-41, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24632979
5.
A high oocyte yield for intracytoplasmic sperm injection treatment is associated with an increased chromosome error rate.
Fertil Steril
; 91(3): 733-8, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18314124
6.
Bis-chelated imine-alkoxytitanium complexes: novel chiral dopants with high helical twisting power in liquid crystals.
Chemistry
; 11(11): 3405-12, 2005 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-15803519
Resultados
1 -
6
de 6
1
Próxima >
>>